Logo     Print Page  Close Window


SEC Filings


8-K
FIBROCELL SCIENCE, INC. filed this Form 8-K on 11/13/2018
Entire Document
 
 
Costs for the FCX-013 program decreased approximately $1.5 million, or 79.5%, to approximately $0.4 million for the nine months ended September 30, 2018, as compared to approximately $1.8 million for the same period in 2017. This decrease was related primarily to decreased costs from Precigen of approximately $1.3 million, as substantially all of the costs of the pre-clinical phase of the FCX-013 program were incurred at the end of 2017, while the first nine months of 2018 has been used for clinical trial start-up activities. Selling, general and administrative expenses decreased 8.1% to approximately $4.7 million for the nine months ended September 30, 2018, as compared to approximately $5.1 million for the same nine-month period in 2017. This decrease was related primarily to lower costs for professional fees. Fibrocell used approximately $10.2 million in cash for operations during the nine months ended September 30, 2018, and used approximately $12.9 million in cash for operations during the nine months ended September 30, 2017. As of September 30, 2018, the Company had cash and cash equivalents of approximately $16.1 million and working capital of approximately $14.6 million. The Company believes that its cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2019. Conference Call and Webcast To participate on the live call, please dial 877-260-1479 (domestic) or +1-334-323-0522 (international), and provide the conference code 7133925 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. About Fibrocell Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Precigen, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell. Trademarks Fibrocell®, the Fibrocell logo, and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners. Forward-Looking Statements This press release contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor